Vycor Medical Releases Financial Results for the Three And Nine Months Ended September 30, 2026

VYCOR MEDICAL INC (VYCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vycor Medical Releases Financial Results for the Three And Nine Months Ended September 30, 2026 BOCA RATON, FL (November 13, 2026) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the three and nine months ended September 30, 2026.

Event · Earnings
Original reporting
Published Nov 16, 2026, 11:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$VYCO
Bearish
high confidence
Mentioned
$VYCO
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VYCOBearishMed
01

Why it matters

The earnings release shows a contraction in core device sales and modest growth in the development division, suggesting near‑term revenue pressure.

02

Market read

First‑time disclosure of a micro‑cap earnings beat with declining metrics; likely to move the stock modestly lower on the day.

03

What to watch

Recent peer‑reviewed studies on the ViewSite system could drive future adoption despite short‑term sales lag.

Relevance 7/10Novelty 8/10Timing: released today (Nov 16 2026)

Background

Vycor Medical (OTCQB:VYCO) operates the ViewSite™ Brain Access System and is developing a visual‑rehab platform, NovaVision.

Company-level read

Ticker impact

$VYCOBearishHigh confidence
Context

Vycor Medical filed an 8‑K reporting Q3 and nine‑month results showing double‑digit revenue declines and lower operating profit.

Expected impact

downward pressure as investors price in lower sales and profit

Evidence & confidence

The disclosed numbers are the first public release and show material deterioration versus the prior year.

Market effects

May weigh on other small‑cap medical device stocks as the decline highlights demand softness.

Limited to U.S. OTC market; no broader regional effect.

Minimal global impact; confined to niche neurosurgical device segment.

Counterpoint

If the company can secure new hospital contracts, the dip may be temporary and present a buying opportunity at lower valuation.

Key entities

  • Vycor Medical Inc.

    Medical device maker reporting Q3 2026 results.

Related articles

$VYCOMed

Vycor Medical Releases Financial Results for the Three And Six Months Ended June 30, 2026

VYCOR MEDICAL INC (VYCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vycor Medical Releases Financial Results for the Three And Six Months Ended June 30, 2026 BOCA RATON, FL (August 14, 2026) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the three and six months ended June 30, 2026. The Company op

$XPMedAI 8/10

XP Q3 2026 slides: asset growth strong, but margin pressure evident

XP Inc. reported Q3 2026 earnings with total client assets up 15% YoY to R$2.2T, but net margins contracted to 26.9%. Revenue grew 8% YoY to R$5.3B, while SG&A expenses rose 12% YoY. Shares fell 4.26% post-earnings. The company is diversifying revenue, with non-investment revenues now 20% of retail revenue. Management expects 10% annual top-line growth in 2027.